Biogenic Ag-Cu Nanoparticles Synthesized with Extract of L. and Evaluation of their Anticancer Potential on PC-3 and LNCaP Cancer Cell Lines.

[BACKGROUND] The anticancer action of biogenic Ag-Cu nanoparticles (NPs) using against PC-3 and LNCaP cell lines in prostate malignancy was investigated.

[MATERIALS AND METHODS] XRD, FTIR, EDAX, FESEM, and TEM were used to illustrate the Ag-Cu NPs. The PC-3 and LNCaP cell lines were used to test the anticancer ability of Ag-Cu NPs. The cytotoxicity was assessed by MMT and flow cytometry. Apoptotic and metastatic-promoting gene expressions were evaluated by real-time PCR. ROS generation was measured.

[RESULTS] NPs are spherical and their average size was 12 ± 9.7 nanometers. The EDAX result indicated the presence of Ag, Cu, and C. The XRD results revealed the NPs' crystalline structure. The results demonstrated a remarkable antiproliferative effect of the nanoparticles, with IC50 values of 15.43 μg/mL for PC-3 and 7.64 μg/mL for LNCaP. The Ag-Cu NPs exhibited a tendency to trigger apoptosis. This was confirmed by analyzing apoptosis-related gene expression. The apoptotic influence of Ag-Cu NPs was suggested to be critical when compared to the control and extract-treated groups by the up-regulation of -related X (), , and , and the down-regulation of . Furthermore, Annexin V-FITC/propidium iodide presented a 23.15% and 22.3% apoptotic ratio of PC-3 and LNCaP cells, respectively. Vascular endothelial growth factor (), and metalloproteinases (MMPs) down-regulation showed that Ag-Cu NPs were hostile to metastasis. Also, ROS generation was estimated at 1261 and 1366 RFU in LNCaP and PC-3 cells treated with green-synthesized Ag-Cu NPs, respectively.

[CONCLUSIONS] The study suggested synthesized Ag-Cu as a potential candidate in prostate cancer therapeutic management.